Effects of allopurinol and febuxostat on uric acid transport and transporter expression in human umbilical vein endothelial cells.


Journal

PloS one
ISSN: 1932-6203
Titre abrégé: PLoS One
Pays: United States
ID NLM: 101285081

Informations de publication

Date de publication:
2024
Historique:
received: 29 01 2024
accepted: 06 06 2024
medline: 21 6 2024
pubmed: 21 6 2024
entrez: 21 6 2024
Statut: epublish

Résumé

Uric acid induces radical oxygen species formation, endothelial inflammation, and endothelial dysfunction which contributes to the progression of atherosclerosis. Febuxostat inhibits BCRP- and allopurinol stimulates MRP4-mediated uric acid efflux in human embryonic kidney cells. We hypothesized that endothelial cells express uric acid transporters that regulate intracellular uric acid concentration and that modulation of these transporters by febuxostat and allopurinol contributes to their different impact on cardiovascular mortality. The aim of this study was to explore a potential difference between the effect of febuxostat and allopurinol on uric acid uptake by human umbilical vein endothelial cells. Febuxostat increased intracellular uric acid concentrations compared with control. In contrast, allopurinol did not affect intracellular uric acid concentration. In line with this observation, febuxostat increased mRNA expression of GLUT9 and reduced MRP4 expression, while allopurinol did not affect mRNA expression of these uric acid transporters. These findings provide a possible pathophysiological pathway which could explain the higher cardiovascular mortality for febuxostat compared to allopurinol but should be explored further.

Identifiants

pubmed: 38905201
doi: 10.1371/journal.pone.0305906
pii: PONE-D-24-03796
doi:

Substances chimiques

Allopurinol 63CZ7GJN5I
Febuxostat 101V0R1N2E
Uric Acid 268B43MJ25
ABCC4 protein, human 0
Multidrug Resistance-Associated Proteins 0
Glucose Transport Proteins, Facilitative 0
SLC2A9 protein, human 0
RNA, Messenger 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

e0305906

Informations de copyright

Copyright: © 2024 van der Pol et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Déclaration de conflit d'intérêts

I have read the journal’s policy and the authors of this manuscript have the following competing interests: FR is a member of the Dutch Medicines Evaluation Board. The other authors have declared that no competing interests exist. This does not alter our adherence to PLOS ONE policies on sharing data and materials.

Auteurs

Karel H van der Pol (KH)

Department of Internal Medicine, Radboud University Medical Center, Nijmegen, The Netherlands.
Department of Pharmacology and Toxicology, Radboud University Medical Center, Nijmegen, The Netherlands.

Jan Koenderink (J)

Department of Pharmacology and Toxicology, Radboud University Medical Center, Nijmegen, The Netherlands.

Jeroen J M W van den Heuvel (JJMW)

Department of Pharmacology and Toxicology, Radboud University Medical Center, Nijmegen, The Netherlands.

Petra van den Broek (P)

Department of Pharmacology and Toxicology, Radboud University Medical Center, Nijmegen, The Netherlands.

Janny Peters (J)

Department of Pharmacology and Toxicology, Radboud University Medical Center, Nijmegen, The Netherlands.

Imke D W van Bunningen (IDW)

Department of Pharmacology and Toxicology, Radboud University Medical Center, Nijmegen, The Netherlands.

Jeanne Pertijs (J)

Department of Pharmacology and Toxicology, Radboud University Medical Center, Nijmegen, The Netherlands.

Frans G M Russel (FGM)

Department of Pharmacology and Toxicology, Radboud University Medical Center, Nijmegen, The Netherlands.

Jim Koldenhof (J)

Applied Stem Cell Technologies, University of Twente, Enschede, The Netherlands.

Wim J Morshuis (WJ)

Department of Cardio-thoracic Surgery, Radboud University Medical Center, Nijmegen, The Netherlands.

Joris van Drongelen (J)

Department of Obstetrics and Gynaecology, Radboud University Medical Center, Nijmegen, The Netherlands.

Tom J J Schirris (TJJ)

Department of Pharmacology and Toxicology, Radboud University Medical Center, Nijmegen, The Netherlands.

Andries van der Meer (A)

Applied Stem Cell Technologies, University of Twente, Enschede, The Netherlands.

Gerard A Rongen (GA)

Department of Internal Medicine, Radboud University Medical Center, Nijmegen, The Netherlands.
Department of Pharmacology and Toxicology, Radboud University Medical Center, Nijmegen, The Netherlands.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH